Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.

Malouf GG, Camparo P, Molinié V, Dedet G, Oudard S, Schleiermacher G, Theodore C, Dutcher J, Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Escudier B.

J Urol. 2011 Jan;185(1):24-9. doi: 10.1016/j.juro.2010.08.092. Epub 2010 Nov 12.

PMID:
21074195
2.

Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis.

Qiu Rao, Bing Guan, Zhou XJ.

Int J Surg Pathol. 2010 Dec;18(6):458-64. doi: 10.1177/1066896910375565. Epub 2010 Jul 18.

PMID:
20643670
3.

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.

Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chilosi M.

Mod Pathol. 2009 Aug;22(8):1016-22. doi: 10.1038/modpathol.2009.58. Epub 2009 Apr 24.

4.

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A.

Am J Surg Pathol. 2008 May;32(5):656-70. doi: 10.1097/PAS.0b013e3181609914.

PMID:
18344867
5.

[Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].

Rao Q, Zhou J, Zhang RS, Ma HH, Zhou HB, Lu ZF, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2010 Sep;39(9):582-6. Chinese.

PMID:
21092583
6.

Translocation carcinoma of the kidney.

Paras FA Jr, MacLennan GT.

J Urol. 2008 May;179(5):2007. doi: 10.1016/j.juro.2008.02.013. Epub 2008 Mar 19. No abstract available.

PMID:
18355851
7.

Molecular heterogeneity of TFE3 activation in renal cell carcinomas.

Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, Aulmann S.

Mod Pathol. 2012 Feb;25(2):308-15. doi: 10.1038/modpathol.2011.169. Epub 2011 Oct 28.

8.

Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.

Mir MC, Trilla E, de Torres IM, Panizo A, Zlotta AR, Van Rhijn B, Morote J.

BJU Int. 2011 Jul;108(2 Pt 2):E71-6. doi: 10.1111/j.1464-410X.2010.09818.x. Epub 2010 Nov 10.

9.

Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH.

Cancer. 2008 Apr 1;112(7):1607-16. doi: 10.1002/cncr.23331.

10.

Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.

Medendorp K, van Groningen JJ, Schepens M, Vreede L, Thijssen J, Schoenmakers EF, van den Hurk WH, Geurts van Kessel A, Kuiper RP.

Cytogenet Genome Res. 2007;118(2-4):157-65. Review.

PMID:
18000366
11.

Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.

Chang IW, Huang HY, Sung MT.

Am J Surg Pathol. 2009 Dec;33(12):1894-901. doi: 10.1097/PAS.0b013e3181ba7a5f.

PMID:
19809274
12.

Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: possible Xp11.2 translocation.

Armah HB, Parwani AV.

Pathology. 2008 Apr;40(3):306-8. doi: 10.1080/00313020701816373. No abstract available.

PMID:
18428054
13.
14.

Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.

Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, Waldert M, Marberger M, Susani M, Haitel A.

Am J Clin Pathol. 2012 May;137(5):761-8. doi: 10.1309/AJCPQ6LLFMC4OXGC.

15.

Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors.

Bambury RM, Battley JE, McCarthy A, Brady C, O'Reilly S, Kelly PJ, O'Brien F, Sweeney P, Fleming S, Mayer NJ, Power DG.

Clin Genitourin Cancer. 2013 Sep;11(3):357-61. doi: 10.1016/j.clgc.2012.12.006. Epub 2013 Jan 16. No abstract available.

PMID:
23332637
16.

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Argani P, Laé M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M.

Am J Surg Pathol. 2005 Feb;29(2):230-40.

PMID:
15644781
17.

Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features.

Suárez-Vilela D, Izquierdo-García F, Méndez-Álvarez JR, Miguélez-García E, Domínguez-Iglesias F.

Int J Surg Pathol. 2011 Aug;19(4):506-9. doi: 10.1177/1066896909340531. Epub 2009 Aug 16.

PMID:
19687027
18.

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B.

Ann Oncol. 2010 Sep;21(9):1834-8. doi: 10.1093/annonc/mdq029. Epub 2010 Feb 12.

19.

[Research advances in Xp11.2 translocation renal cell carcinoma].

Huang JH, Zhou FJ.

Ai Zheng. 2008 Sep;27(9):1006-8. Review. Chinese.

PMID:
18799045
20.

Renal cell carcinoma with t(6;11) translocation: a patient case with a novel Alpha-TFEB fusion point.

Zhan HQ, Wang CF, Zhu XZ, Xu XL.

J Clin Oncol. 2010 Dec 1;28(34):e709-13. doi: 10.1200/JCO.2010.30.3172. Epub 2010 Sep 7. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk